Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors
- PMID: 18782902
- PMCID: PMC2571066
- DOI: 10.2337/dc08-1013
Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors
Abstract
Objective: The purpose of this study was to assess incidence of and risk factors for recurrent cardiovascular disease (CVD) in type 2 diabetes.
Research design and methods: We estimated the incidence of recurrent cardiovascular events in type 2 diabetic patients, aged 40-97 years, followed by a network of diabetes clinics. The analysis was conducted separately for 2,788 patients with CVD at enrollment (cohort A) and for 844 patients developing the first episode during the observation period (cohort B).
Results: During 4 years of follow-up, in cohort A the age-adjusted incidence of a recurrent event (per 1,000 person-years) was 72.7 (95% CI 58.3-87.1) in men and 32.5 (21.2-43.7) in women, whereas in cohort B it was 40.1 (17.4-62.9) in men and 22.4 (12.9-32.0) in women. After controls were included for potential predictors (familial CVD, obesity, smoking, diabetes duration, glycemic control, microvascular complications, geographic area, and antihypertensive and lipid-lowering treatment), male sex, older age, and insulin use were significant independent risk predictors (cohort A) and serum triglyceride levels >/=1.69 mmol/l emerged as the only metabolic (negative) prognostic factor (cohort B). In both cohorts, a prior CVD episode, especially myocardial infarction, was by far the strongest predictor of recurrent CVD.
Conclusions: Approximately 6% of unselected diabetic patients in secondary prevention develop recurrent major CVD every year. Those with long-standing previous CVD show a higher incidence of recurrence. Male sex, age, high triglyceride levels, and insulin use are additional predictors of recurrence.
References
- 
    - Abbott RD, Donahue RP, Kannel WB, Wilson PW: The impact of diabetes on survival following myocardial infarction in men vs. women: the Framingham Study. JAMA 260:3456–3460, 1988 - PubMed
 
- 
    - Miettinen H, Lehto S, Salomaa VV, Mähönen M, Niemelä M, Haffner SM, Pyörälä K, Tuomilheto J: Impact of diabetes on mortality after the first myocardial infarction: the FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 21:69–75, 1998 - PubMed
 
- 
    - Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality form coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234, 1998 - PubMed
 
- 
    - Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM, PROactive Investigators: The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study. J Am Coll Cardiol 49:1772–1780, 2007 - PubMed
 
- 
    - The DAI Study Group: Prevalence of coronary heart disease in a cohort of type 2 diabetic patients in Italy: the DAI study. Diabet Med 21:738–745, 2004 - PubMed
 
Publication types
MeSH terms
Substances
LinkOut - more resources
- Full Text Sources
- Other Literature Sources
- Medical
 
        